越来越多证据告诉我们，帕金森病这一全球增长最快的神经系统疾病或许能分成两种不同类型，一种生发自脑中，另一种源于身体而向脑进击。关于疾病 的全新认知能否带来我们亟需的新疗法？ 一、消失的心脏 丹麦奥胡斯大学的神经科学家佩尔·博格哈默（Per Borghammer）在大约二十年前有过一次"顿悟"，来自那时他研读的一篇论文。文章作者试图探究快速眼 动睡眠行为障碍（RBD）是否为帕金森病这一神经系统疾病的早期表现之一。 RBD是一种最常见的睡眠行为障碍，此病的症状为人在睡梦中通过肢体演绎梦境——后期发展出帕金森病的人群往往会在较早阶段经历RBD。 不过作者团队并未从大脑入手，而是选择寻找心脏部位的神经细胞损失。 历来被认为与大脑神经元退化相关的帕金森病实际上也影响心脏中那些控制心率、血压等自主神经功能的神经元。博格哈默表示："所有这些RBD患者的 心脏，似乎都完全'隐形'了，'消失'了。" 当然，这并非字面意义上的隐形和消失，只是他们体内负责产生去甲肾上腺素的神经元严重耗竭了，而去甲肾上腺素能调控心率，结果他们的心脏无法通 过放射性示踪剂扫描来显影。此类神经元损失本与帕金森病相关，但当时这些RBD人群均未确诊帕金森病 ...

Core Insights - The humanoid robot industry is entering a critical phase, transitioning from initial skepticism to increased market interest and potential applications in various sectors such as logistics, healthcare, and commercial services [1][2] - The collaboration between Guosheng Securities and Jinding Capital aims to provide forward-looking industry research and strategic support for listed companies to capitalize on the humanoid robot opportunity [1] Industry Overview - The humanoid robot industry has evolved from being undervalued to experiencing enthusiasm in both primary and secondary markets, indicating a significant shift in perception [1] - The primary market is now focusing on sales metrics, with expectations for startup sales to exceed 100 million yuan in 2024, reflecting a critical change in industry dynamics [1] Challenges Facing the Industry - Three main constraints are identified that hinder the development of the humanoid robot industry: insufficient data accumulation in software, unresolved hardware issues such as heat dissipation, and the need for practical application scenarios [2] - The industry is currently debating the necessity of humanoid robots replacing human roles, highlighting the need for valuable application scenarios to be realized [2]

SAN DIEGO, June 03, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced two oral presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress, taking place June 13-16, 2025, in Glasgow, United Kingdom and virtually. The presentation details a ...

Core Insights - Genmab A/S announced promising results from the Phase 1/2 RAINFOL™-01 trial for rinatabart sesutecan (Rina-S), showing a 50.0% confirmed objective response rate (ORR) in advanced endometrial cancer patients [2][3][6] - The study involved 64 heavily pre-treated patients, with a median follow-up of 7.7 months, and demonstrated significant anti-tumor activity [3][4] - Rina-S is an investigational antibody-drug conjugate targeting folate receptor alpha (FRα), with ongoing evaluations in various cancers [10][11] Company Overview - Genmab is focused on developing innovative antibody-based medicines to address unmet needs in cancer treatment, particularly for gynecologic cancers [5][12] - The company has a robust pipeline, including bispecific T-cell engagers and antibody-drug conjugates, aiming to transform cancer treatment by 2030 [12] Clinical Trial Details - The RAINFOL-01 trial is an open-label, multicenter study evaluating Rina-S in solid tumors, with specific cohorts for endometrial cancer [6][7] - The B2 cohort results indicate that Rina-S 100 mg/m led to a 50.0% ORR, while the 120 mg/m cohort showed a 47.1% ORR, with no median duration of response reached [3][4][6] Treatment Context - Advanced endometrial cancer has limited treatment options after progression on standard therapies, highlighting the need for new therapies like Rina-S [8][9] - The incidence and mortality rates of endometrial cancer are increasing, emphasizing the urgency for effective management strategies [8] Safety Profile - Common treatment emergent adverse events included diarrhea, dyspnea, and urinary tract infections, with serious adverse events occurring in 31.8% and 50.0% of patients in the 100 mg/m and 120 mg/m cohorts, respectively [4][5] - No significant ocular toxicities or interstitial lung disease were observed, which are often concerns with antibody-drug conjugates [4]

Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Data continue to support planned initiation of pivotal study in mid-2025 Next-generation triplet combinations with atirmociclib (CDK4-selective) & ribociclib ongoing CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery pro ...

过去三年，指数投资的魅力正在显现。指数化投资受到越来越多的投资者认可，指数基金规模快速发 展，增强策略指数基金产品更是获得投资者的火热布局。 今年以来，已经发行和正在发行的股票指数增强策略基金达到57只（不同份额），整体规模超过290亿 元（数据来自万得信息）。近期，股票指数增强策略基金阵营又迎新品——5月19日起发行的华商中证 500指数增强基金（A：023826，C：023827）为股票指数增强型基金，将主要利用华商基金自主研发的 量化选股模型，在保持对标的指数（中证500指数）紧密跟踪的前提下，力争实现超越目标指数的投资 收益。 中盘成长宽基：中证500指数之魅力 如今，中证500指数已成为A股市场最具代表性的中盘成长宽基指数之一。 中证500指数由全部A股中剔除沪深300指数成份股及总市值排名前300名的股票后，总市值排名靠前的 500只股票组成，综合反映A股市场偏中盘市值公司的股票价格表现。 该指数聚焦了一批符合产业政策导向的成长蓝筹及细分行业龙头，兼具成长、创新和价值属性，在新质 生产力加速培育和形成的过程中，相关企业长期投资价值有望进一步显现。以中证500指数为跟踪标的 的指数化投资，或将迎来新 ...

Core Insights - The article discusses the challenges faced by patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and seasonal allergic rhinitis (SAR), highlighting the limitations of traditional treatments and the emergence of innovative therapies like Dupilumab [1][2][3] Group 1: Patient Challenges - Many patients with CRSwNP and SAR experience inadequate treatment outcomes, with about 50% of CRSwNP patients facing recurrence of symptoms despite standardized medical and surgical interventions [1] - A significant percentage of patients with moderate to severe SAR do not achieve effective symptom control even when using potent nasal corticosteroids and antihistamines [1][3] Group 2: Innovative Treatment Development - The approval of Supilumab (康悦达) by the National Medical Products Administration (NMPA) for CRSwNP in December 2024 marks a significant advancement in treatment options [2] - Supilumab is the first IL-4Rα biological agent approved for SAR, expanding its therapeutic applications [2][3] Group 3: Clinical Efficacy - In clinical trials, Supilumab demonstrated significant efficacy, with 72% of patients showing notable reduction in nasal polyps within two weeks of treatment, and 81% achieving at least a 50% reduction by 24 weeks [3][4] - For SAR, 52% of patients achieved nasal airflow within four days of treatment, and 84% reported mild or no nasal symptoms after four weeks [4] Group 4: Market Potential - The global market for IL-4Rα-targeted drugs is projected to grow significantly, with estimates reaching $12.2 billion by 2024 and $28.7 billion by 2030, reflecting a compound annual growth rate of 15.2% [5] - The competitive landscape is evolving, with domestic companies like 康诺亚 gaining traction in the IL-4Rα drug market, challenging established players [5][6] Group 5: Future Directions - 康诺亚 is actively exploring additional indications for Supilumab, including adolescent atopic dermatitis and nodular prurigo, aiming to address unmet clinical needs and reduce treatment costs [9][11] - The company is also developing a diverse pipeline of therapies, including second-generation bispecific antibodies and ADCs, to enhance treatment options for various diseases [10][11]

誉衡药业（002437）公告，公司于2025年5月23日与兴和制药有限公司就佩玛贝特片签订了共同推广协 议。该协议将于2025年6月1日生效，初始期限至2027年12月31日，之后可自动续期。根据协议，兴和制 药授权誉衡药业在指定区域推广佩玛贝特片，并支付服务费及推广支持费。佩玛贝特片是全球首个新型 高选择性PPARα调节剂，主要用于降低非家族型高甘油三酯血症成年患者的甘油三酯水平。此次合作将 丰富誉衡药业的产品线，增强其在心脑血管领域的竞争力。 ...

建筑材料 行业专题报告 hyzqdatemark 2025 年 05 月 22 日 戴铭余 SAC：S1350524060003 daimingyu@huayuanstock.com 王彬鹏 SAC：S1350524090001 wangbinpeng@huayuanstock.com 郦悦轩 SAC：S1350524080001 liyuexuan@huayuanstock.com 朱芸 SAC：S1350524070001 zhuyun@huayuanstock.com 证券研究报告 唐志玮 tangzhiwei@huayuanstock.com 板块表现： 由单边下行走向结构分化，赛道及龙头α开始显现 投资评级： 看好（维持） ——建材行业 2024 年报及 2025 年一季报综述 投资要点： 风险提示：经济恢复不及预期，化债力度不及预期，房地产政策不及预期 请务必仔细阅读正文之后的评级说明和重要声明 | 1. 综述:行业压力仍存,结构性拐点逐步显现…………………………………………………………………………………… 5 | | --- | | 2. 消费建材:行业逐步探底,结构分化开始显现. | | 3. ...

– Rademikibart significantly improved airway function, as measured by FEV1 , within a day and significantly reduced acute exacerbations in patients with inflammation-mediated chronic asthma strongly supporting ongoing Phase 2 acute exacerbation studies in asthma and COPD which are expected to report topline data in 1H26 – – New preclinical data highlights differentiated structural and molecular dynamics of rademikibart with enhanced interleukin-4 receptor alpha (IL-4Rα) inhibition compared to dupilumab prov ...